

**Institute of Aerospace Medicine**  
**Institute Seminar, May 28, 2019, *Abstract***

---

**Dr. Christian Glöckner**

Key Expert Technology, NEO New Oncology GmbH,  
A Siemens Healthineers Company, Köln, Germany

---

**Next Generation Sequencing for an improved decision making on cancer therapies.**

Next Generation Sequencing (NGS) has developed quickly in the last decade from an expensive research tool to a technology fit for clinical use. NEO New Oncology GmbH, a start-up company from Cologne, employs NGS and the analysis of NGS data to support decision making in a routine clinical setting. Cancer is a disease of the human genome and thus knowledge of the underlying causes play a critical role in its treatment. Advances in pharmacological research have led to novel drugs that target specific mutations in different cancers and patient stratification based on genetic information is key for an informed and effective treatment.